JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Journal of Clinical Pathology 2006;59:150-152; doi:10.1136/jcp.2004.024687
Copyright © 2006 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nowicki, M
Right arrow Articles by Miskowiak, B
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nowicki, M
Right arrow Articles by Miskowiak, B
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Neuroblastoma

ORIGINAL ARTICLE

Prognostic value of stage IV neuroblastoma metastatic immunophenotype in the bone marrow: preliminary report

M Nowicki1, D Ostalska-Nowicka2, B Miskowiak3

1 Department of Histology and Embryology, Poznan University of Medical Sciences, Swiecickiego 6, 60-781 Poznan, Poland
2 Department of Cardiology and Nephrology, Poznan University of Medical Sciences
3 Department of Optometry and Biology of the Visual System, Poznan University of Medical Sciences

Correspondence to:
Dr M Nowicki
Department of Histology and Embryology, Poznan University of Medical Sciences, ul. Swiecickiego 6, 60-781 Poznan, Poland; mnowicki{at}amp.edu.pl Aim: To correlate the immunophenotype of metastatic cells in the bone marrow of patients with neuroblastoma with early treatment failure.

Methods: The studies were performed on bone marrow material obtained from children treated in the department of paediatric oncology, haematology, and transplantology, Poznan University of Medical Sciences, Poland from 1996 to 2003. Immunocytochemical analysis of nervous tissue markers (using the immunomax technique) was performed on 108 bone marrow preparations obtained from 36 children diagnosed with neuroblastoma (stage IV with bone marrow metastases). The analysis included expression of PGP 9.5 protein, substance P, chromogranin A, bombesin, galanin, neuropeptide Y (NPY), and vasoactive intestinal peptide in neuroblastoma metastatic cells defined by the expression of neurone specific enolase.

Results: Nineteen relapses occurred within 12 months of the end of treatment. Correlation between the various markers studied and early treatment failure, using Fisher’s exact test, revealed that chromogranin A and NPY are strong indicators of an unfavourable prognosis in patients with stage IV neuroblastoma (p < 0.001 and p < 0.0002, respectively).

Conclusion: Determination of metastatic cell immunophenotypes in bone marrow (particularly chromogranin A and NPY) may help establish the short term prognosis in children with neuroblastoma.


Abbreviations: NPY, neuropeptide Y; VIP, vasoactive intestinal peptide

Keywords: neuroblastoma; prognosis; neuropeptide; immunohistochemistry




This article has been cited by other articles:


Home page
J. Clin. Pathol.Home page
M. Nowicki, D. Ostalska-Nowicka, B. Kondraciuk, and B. Miskowiak
The significance of substance P in physiological and malignant haematopoiesis
J. Clin. Pathol., July 1, 2007; 60(7): 749 - 755.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2006 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.